pravastatin has been researched along with Stomach Neoplasms in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Banales, JM; Bujanda, L; Cosme, A; Eizaguirre, E; Hijona, E; Marín, JJ; Perugorria, MJ; Rodríguez-González, A; Sarasqueta, C | 1 |
| de Jongh, FE; Eskens, FA; Konings, IR; Sleijfer, S; van der Gaast, A; van der Wijk, LJ | 1 |
| Gebhardt, A; Niendorf, A | 1 |
1 trial(s) available for pravastatin and Stomach Neoplasms
| Article | Year |
|---|---|
The addition of pravastatin to chemotherapy in advanced gastric carcinoma: a randomised phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Epirubicin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pravastatin; Stomach Neoplasms | 2010 |
2 other study(ies) available for pravastatin and Stomach Neoplasms
| Article | Year |
|---|---|
Effect of pravastatin on the survival of patients with advanced gastric cancer.
Topics: Aged; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Neoplasm Staging; Pravastatin; Prognosis; Stomach Neoplasms; Survival Rate | 2016 |
Effects of pravastatin, a hydroxymethylglutaryl-CoA reductase inhibitor, on two human tumour cell lines.
Topics: Blotting, Southern; Breast Neoplasms; Cell Division; Cholesterol, LDL; Dose-Response Relationship, Drug; Gene Expression; Humans; Hydroxymethylglutaryl CoA Reductases; Immunohistochemistry; Polymerase Chain Reaction; Pravastatin; RNA, Messenger; RNA, Neoplasm; Stomach Neoplasms; Tumor Cells, Cultured | 1995 |